Table II.

Effect of Various Retinoids on Proliferation of WT and Mutant F9 Cells

Treatment		WT and mutant F9 cells
		WT		RXRα−/−		RARα−/−		RXRα−/− RARα−/−		RARγ−/−		RXRα−/− RARγ−/−
Ethanol		100		100		100		100		100		100
1 μM tRA		21		42		22		46		28		112
1 μM panRXR  agonist		100		100		100		100		100		100
10 nM RARα  agonist		100		100		100		100		100		124
100 nM RARα  agonist		100		100		100		100		100		143
50 nM RARβ  agonist		100		100		ND		ND		100		ND
500 nM RARβ  agonist		100		100		100		100		100		120
10 nM RARγ  agonist		100		100		100		100		100		100
100 nM RARγ  agonist		37		51		30		49		100		100
10 nM RARα  + 1 μM  panRXR  agonists		100		100		100		100		100		130
100 nM RARα  + 1 μM  panRXR  agonists		56		100		100		100		40		146
50 nM RARβ  + 1 μM  panRXR  agonists		100		100		ND		ND		53		ND
500 nM RARβ  + 1 μM  panRXR  agonists		100		100		100		100		47		154
10 nM RARγ  + 1 μM  panRXR  agonists		60		81		42		77		100		100
100 nM RARγ  + 1 μM  panRXR  agonists		31		44		ND		ND		100		ND

WT and mutant F9 cells were treated for 6 d in monolayer culture with the indicated retinoids. In each case, the number of cells was expressed in percent relative to the number of cells grown in 0.1% ethanol, which was taken as 100%. ND, not determined. These values correspond to the average of at least three experiments (± 10%). RARα, RARβ, RARγ, and panRXR specific agonists were as in Table I.